@prefix : <http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#> .
@prefix mp: <http://purl.org/mp/> .
@prefix oa: <http://www.w3.org/ns/oa#> .
@prefix opv: <http://inab.certh.gr/OpenPVSignal> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xml: <http://www.w3.org/XML/1998/namespace> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix openpvsignal: <http://purl.org/OpenPVSignal/OpenPVSignal.owl> .
@base <http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl> .

<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl> rdf:type owl:Ontology ;
                                                                                                       owl:imports <http://purl.org/OpenPVSignal/OpenPVSignal.owl> ;
                                                                                                       rdfs:isDefinedBy "https://apps.who.int/iris/handle/10665/277447/"^^xsd:anyURI ;
                                                                                                       rdfs:label "Aflibercept and deep vein thrombosis/pulmonary embolism"^^rdfs:Literal ;
                                                                                                       owl:versionInfo "draft-v0.95-20210510"@en .

#################################################################
#    Object Properties
#################################################################

###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element
<http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> rdf:type owl:ObjectProperty .


###  http://purl.org/mp/publishedBy
mp:publishedBy rdf:type owl:ObjectProperty .


###  http://purl.org/mp/referencedBy
mp:referencedBy rdf:type owl:ObjectProperty .


###  http://purl.org/mp/references
mp:references rdf:type owl:ObjectProperty .


#################################################################
#    Individuals
#################################################################

###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#AcetylsalicylicAcid
:AcetylsalicylicAcid rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A01AD05" ,
                                                                                  "B01AC06" ,
                                                                                  "B01AC56" ,
                                                                                  "C10BX01" ,
                                                                                  "C10BX02" ,
                                                                                  "C10BX04" ,
                                                                                  "C10BX05" ,
                                                                                  "C10BX06" ,
                                                                                  "C10BX08" ,
                                                                                  "M01BA03" ,
                                                                                  "N02BA01" ,
                                                                                  "N02BA51" ,
                                                                                  "N02BA71" ;
                     rdfs:label "Acetylsalicylic acid" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Aflibercept
:Aflibercept rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :ColonCancerMetastatic ,
                                                                                         :DiabeticRetinalOedema ,
                                                                                         :Macular_oedema ,
                                                                                         :Myopic_choroidal_neovascularisation ,
                                                                                         :Neovascularage-relatedMacularDegeneration ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#hasClass> <http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#VEGF/VEGFR_(Vascular_Endothelial_Growth_Factor)_inhibitors> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_mechanism> :Mechanism_of_Aflibercept ,
                                                                           :Pharmacokinetics_of_aflibercept_intravitrial_administration ,
                                                                           <http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Pharmacokinetics_of_aflibercept_(IV)_for_cancer_patients> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "L01XX44" ,
                                                                          "S01LA05" ;
             rdfs:label "Aflibercept" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Aflibercept_product_label
:Aflibercept_product_label rdf:type owl:NamedIndividual ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Structured_Product_Labels_information> ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Warning_Information> ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Arterial_thrombosis ,
                                                                                                    :DeepVeinThrombosis ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Aflibercept ;
                           mp:references :Ref.1 ,
                                         :Ref.2 ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Arterial and venous thromboembolic events are both included in the product label for aflibercept for its use in the cancer indication. In the label for its use in ocular indications, only a theoretical risk of arterial thromboembolic events is mentioned.1,2" ;
                           rdfs:label "Aflibercept product label" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Air_hunger
:Air_hunger rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R06.0" ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10001529 ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Air hunger" ;
            rdfs:label "Air hunger" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Allopurinol
:Allopurinol rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "M04AA01" ,
                                                                          "M04AA51" ;
             rdfs:label "Allopurinol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Amlodipine
:Amlodipine rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C08CA01" ,
                                                                         "C08GA02" ,
                                                                         "C09BB03" ,
                                                                         "C09BB04" ,
                                                                         "C09BB07" ,
                                                                         "C09BX01" ,
                                                                         "C09DB01" ,
                                                                         "C09DB02" ,
                                                                         "C09DB04" ,
                                                                         "C09DB05" ,
                                                                         "C09DB06" ,
                                                                         "C09DB07" ,
                                                                         "C09DX01" ,
                                                                         "C09DX03" ,
                                                                         "C09XA53" ,
                                                                         "C09XA54" ,
                                                                         "C10BX03" ,
                                                                         "C10BX07" ,
                                                                         "C10BX09" ,
                                                                         "C10BX11" ;
            rdfs:label "Amlodipine" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Arterial_thrombosis
:Arterial_thrombosis rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I74" ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10003178 ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Arterial thrombosis" ;
                     rdfs:label "Arterial thrombosis" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Atorvastatin
:Atorvastatin rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C10AA05" ,
                                                                           "C10BA05" ,
                                                                           "C10BX03" ,
                                                                           "C10BX06" ,
                                                                           "C10BX08" ,
                                                                           "C10BX11" ;
              rdfs:label "Atorvastatin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Bisoprolol
:Bisoprolol rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C07AB07" ,
                                                                         "C07BB07" ,
                                                                         "C07FB07" ;
            rdfs:label "Bisoprolol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Budesonide
:Budesonide rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A07EA06" ;
            rdfs:label "Budesonide" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Buprenorphine
:Buprenorphine rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N02AE01" ;
               rdfs:label "Buprenorphine" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Candesartan
:Candesartan rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C09CA06" ,
                                                                          "C09DA06" ;
             rdfs:label "Candesartan" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ChestPain
:ChestPain rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R07.9" ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10008479 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Chest pain" ;
           rdfs:label "Chest pain" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Citalopram
:Citalopram rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N06AB04" ;
            rdfs:label "Citalopram" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Clinical_trial_report_for_Aflibercept
:Clinical_trial_report_for_Aflibercept rdf:type owl:NamedIndividual ,
                                                <http://purl.obolibrary.org/obo/OAE_0001182> ,
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Clinical_trial_information> ;
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Aflibercept ;
                                       mp:references :Ref.11 ;
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "within a review of clinical trial data supplied to the US FDA, an exploratory subgroup analysis in a Phase 3 study (VIEW2) was identified which did not reveal any clinically relevant influence of gender on the plasma concentrations of free aflibercept or aflibercept:VEGF complex" ;
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_reporter_type> "clinical trial report" ;
                                       rdfs:label "Clinical trial report for Aflibercept" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ColonCancerMetastatic
:ColonCancerMetastatic rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "C18.9" ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10055114 ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Colon cancer metastatic" ;
                       rdfs:label "Colon cancer metastatic" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#DeepVeinThrombosis
:DeepVeinThrombosis rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I82.409" ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10051055 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Deep vein thrombosis" ;
                    rdfs:label "Deep vein thrombosis" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Deep_Vein_Thrombosis
:Deep_Vein_Thrombosis rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :DeepVeinThrombosis ;
                      mp:references :Ref.3 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """\"Deep venous thrombosis (DVT) is the formation of
a blood clot, or thrombus, in one of the deep veins
of the body, most commonly in veins of the lower
extremities. The mechanism of thrombus
formation typically involves a combination of
decreased blood flow, injury to the blood vessel
wall (endothelium), and an increased tendency to
clot. The annual incidence of DVT in the USA has
been estimated to be 80 cases per 100,000. Of the
more than 200,000 people that develop venous
thrombosis in that country each year, 50,000
cases are complicated by pulmonary embolism.3
Deep venous thrombosis usually affects individuals
older than 40 years, with increasing incidence with
age.\"""" ;
                      rdfs:label "Deep Vein Thrombosis pathophysiology" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Deep_vein_thrombosis_leg
:Deep_vein_thrombosis_leg rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I82.40" ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10065052 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Deep vein thrombosis leg" ;
                          rdfs:label "Deep vein thrombosis leg" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#DiabeticRetinalOedema
:DiabeticRetinalOedema rdf:type owl:NamedIndividual ,
                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "E11.351" ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10012688 ;
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Diabetic retinal oedema" ;
                       rdfs:label "Diabetic retinal oedema" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Difficulty_breathing_Air
:Difficulty_breathing_Air rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R06.00" ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10006338 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Breathing difficult" ;
                          rdfs:label "Difficulty breathing" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Doxazosin
:Doxazosin rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C02CA04" ;
           rdfs:label "Doxazosin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Doxepin
:Doxepin rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N06AA12" ;
         rdfs:label "Doxepin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#DyspnoeaExertional
:DyspnoeaExertional rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R06.09" ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10013971 ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Dyspnoea exertional" ;
                    rdfs:label "Dyspnoea exertional" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#EU_labelling
:EU_labelling rdf:type owl:NamedIndividual ,
                       <http://purl.obolibrary.org/obo/OAE_0001197> ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Structured_Product_Labels_information> ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Warning_Information> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Aflibercept ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "The EU labelling for aflibercept notes that gender was found to be a significant covariate for explaining the inter-individual variability of free aflibercept clearance and volume. Males exhibited a 15.5% higher clearance and a 20.6% higher volume of distribution compared to females." ;
              rdfs:label "EU labelling" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#EicosapentaenoicAcid
:EicosapentaenoicAcid rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C10AX06 " ;
                      rdfs:label "Eicosapentaenoic acid" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Empagliflozin
:Empagliflozin rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A10BD19" ,
                                                                            "A10BD20" ,
                                                                            "A10BK03" ;
               rdfs:label "Empagliflozin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Epidemiological__studies_regarding_gender-specific_baseline_risk_for__DVT
:Epidemiological__studies_regarding_gender-specific_baseline_risk_for__DVT rdf:type owl:NamedIndividual ,
                                                                                    <http://purl.obolibrary.org/obo/OAE_0001197> ;
                                                                           mp:references :Ref.10 ,
                                                                                         :Ref.3 ,
                                                                                         :Ref.9 ;
                                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "There are conflicting results from epidemiological studies regarding gender-specific baseline risk for DVT 3,9-10. In the most recent publication on this topic, an increased risk in men was estimated, and the authors note that “…the pathophysiology behind these observations has yet to be unravelled” and “… this risk difference may have implications for future sex- specific treatment and prevention strategies for venous thrombosis.” 9" ;
                                                                           rdfs:label "Epidemiological studies regarding gender-specific baseline risk for DVT" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Estradiol
:Estradiol rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "G02BB01" ,
                                                                        "G03AA14" ,
                                                                        "G03AB08" ,
                                                                        "G03CA03" ,
                                                                        "G03CA53" ,
                                                                        "G03EA01" ,
                                                                        "G03EA02" ,
                                                                        "G03EA03" ,
                                                                        "G03FA01" ,
                                                                        "G03FA02" ,
                                                                        "G03FA03" ,
                                                                        "G03FA04" ,
                                                                        "G03FA05" ,
                                                                        "G03FA06" ,
                                                                        "G03FA07" ,
                                                                        "G03FA08" ,
                                                                        "G03FA09" ,
                                                                        "G03FA10" ,
                                                                        "G03FA11" ,
                                                                        "G03FA12" ,
                                                                        "G03FA13" ,
                                                                        "G03FA14" ,
                                                                        "G03FA15" ,
                                                                        "G03FA16" ,
                                                                        "G03FA17" ,
                                                                        "G03FB01" ,
                                                                        "G03FB02" ,
                                                                        "G03FB03" ,
                                                                        "G03FB04" ,
                                                                        "G03FB05" ,
                                                                        "G03FB06" ,
                                                                        "G03FB07" ,
                                                                        "G03FB08" ,
                                                                        "G03FB09" ,
                                                                        "G03FB10" ,
                                                                        "G03FB11" ,
                                                                        "G03FB12" ,
                                                                        "G03HB01" ;
           rdfs:label "Estradiol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Eye_disorders
:Eye_disorders rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "H57.9" ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10015919 ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Eye disorders" ;
               rdfs:label "Eye disorders" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Fenofibrate
:Fenofibrate rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C10AB05" ,
                                                                          "C10BA03" ,
                                                                          "C10BA04" ;
             rdfs:label "Fenofibrate" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Finasteride
:Finasteride rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "D11AX10" ,
                                                                          "G04CA51" ,
                                                                          "G04CB01" ;
             rdfs:label "Finasteride" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#FolicAcid
:FolicAcid rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B03AE01" ,
                                                                        "B03AE02" ,
                                                                        "B03BB01" ,
                                                                        "B03BB51" ;
           rdfs:label "Folic Acid" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Formoterol
:Formoterol rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "R03AC13" ;
            rdfs:label "Formoterol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Furosemide
:Furosemide rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C03CA01" ,
                                                                         "C03CB01" ,
                                                                         "C03EB01" ,
                                                                         "G01AE10" ;
            rdfs:label "Furosemide" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#GlycerylTrinitrate
:GlycerylTrinitrate rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C01DA02" ,
                                                                                 "C01DA52" ;
                    rdfs:label "Glyceryl trinitrate" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Headache
:Headache rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R51" ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10019211 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Headache" ;
          rdfs:label "Headache" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Heparinoid
:Heparinoid rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C05BA" ;
            rdfs:label "Heparinoid" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Hypertension
:Hypertension rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I10" ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10020772 ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hypertension" ;
              rdfs:label "Hypertension" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Hyperventilation
:Hyperventilation rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R06.4" ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10020910 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Hyperventilation" ;
                  rdfs:label "Hyperventilation" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Hypromellose
:Hypromellose rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "S01KA02" ;
              rdfs:label "Hypromellose" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#IC005_for_aflibercept_and_DVT_for_females
:IC005_for_aflibercept_and_DVT_for_females rdf:type owl:NamedIndividual ,
                                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component_005_(IC005)> ;
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :DeepVeinThrombosis ;
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Aflibercept ;
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_creation_date> "31/12/2017"^^xsd:date ;
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> -2.15 ;
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_number_of_reports> 9 ;
                                           rdfs:label "IC005 for aflibercept and DVT for females" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#IC005_for_aflibercept_and_DVT_for_males
:IC005_for_aflibercept_and_DVT_for_males rdf:type owl:NamedIndividual ,
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component_005_(IC005)> ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :DeepVeinThrombosis ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Aflibercept ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_creation_date> "31/12/2017"^^xsd:date ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 0.21 ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_number_of_reports> 19 ;
                                         rdfs:label "IC005 for aflibercept and DVT for males" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#IC005_for_aflibercept_and_pulmonary_embolism_for_females
:IC005_for_aflibercept_and_pulmonary_embolism_for_females rdf:type owl:NamedIndividual ,
                                                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component_005_(IC005)> ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :PulmonaryEmbolism ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Aflibercept ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_creation_date> "31/12/2017"^^xsd:date ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> -0.55 ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_number_of_reports> 21 ;
                                                          rdfs:label "IC005 for aflibercept and pulmonary embolism for females" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#IC005_for_aflibercept_and_pulmonary_embolism_for_males
:IC005_for_aflibercept_and_pulmonary_embolism_for_males rdf:type owl:NamedIndividual ,
                                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component_005_(IC005)> ;
                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :PulmonaryEmbolism ;
                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Aflibercept ;
                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_creation_date> "31/12/2017"^^xsd:date ;
                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 1.02 ;
                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_number_of_reports> 33 ;
                                                        rdfs:label "IC005 for aflibercept and pulmonary embolism for males" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Intravitreal_dose_of_aflibercept
:Intravitreal_dose_of_aflibercept rdf:type owl:NamedIndividual ,
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Dosage> ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "In the ocular indications, aflibercept is administered intravitreally as a 2 mg dose, to be repeated every month for three consecutive months, followed by every other month" ;
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_dose_value> "2 mg" ;
                                  rdfs:label "Intravitreal dose of aflibercept" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Intravitreal_intake_form
:Intravitreal_intake_form rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Intake_Form> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Aflibercept ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_form_of_intake> "other" ;
                          rdfs:label "Intravitreal intake form" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Intravitreal_usage
:Intravitreal_usage rdf:type owl:NamedIndividual ,
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug_Usage> ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#concerns_indication_for_use> :Eye_disorders ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_related_with_drug_intake> :Intravitreal_intake_form ;
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Aflibercept ;
                    rdfs:label "Intravitreal usage" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Isosorbide_mononitrate
:Isosorbide_mononitrate rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C01DA14" ;
                        rdfs:label "Isosorbide mononitrate" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Lactullose
:Lactullose rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A06AD11" ;
            rdfs:label "Lactulose" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Levothyroxine
:Levothyroxine rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "H03AA01" ;
               rdfs:label "Levothyroxine" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Lovisa_Sandberg
:Lovisa_Sandberg rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Author> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_affiliation> "Uppsala Monitoring Centre" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_first_name> "Lovisa" ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_last_name> "Sandberg" ;
                 rdfs:label "Lovisa Sandberg" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Macular_oedema
:Macular_oedema rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "H34.8190" ,
                                                                             "H34.8390" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10025415 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Macular oedema" ;
                rdfs:label "Macular oedema" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Male_gender_as_a_potential_risk_group
:Male_gender_as_a_potential_risk_group rdf:type owl:NamedIndividual ,
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> ;
                                       mp:references :Ref.10 ,
                                                     :Ref.11 ,
                                                     :Ref.12 ,
                                                     :Ref.13 ,
                                                     :Ref.14 ,
                                                     :Ref.15 ,
                                                     :Ref.16 ,
                                                     :Ref.3 ,
                                                     :Ref.9 ;
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "The increased disproportionality of the ADRs of deep vein thrombosis and pulmonary embolism in males compared to females suggests that male gender may be a potential risk group for thromboembolic disease caused by aflibercept . There are conflicting results from epidemiological studies regarding gender-specific baseline risk for DVT 3,9-10. In the most recent publication on this topic, an increased risk in men was estimated, and the authors note that “…the pathophysiology behind these observations has yet to be unravelled” and “… this risk difference may have implications for future sex- specific treatment and prevention strategies for venous thrombosis.” 9 There was a total of 46 reports of DVT and/or PE for aflibercept in males compared to 28 reports in  females. 67% (31) of the male reports were between the ages of 45 to 74. Sixty four percent (18) of the female reports were 65 years and older. Reports were distributed between the Americas, Europe and Oceania for both genders; Asia had reports only for males (four reports). When product trade name was available, males had a greater proportion of reports for Zaltrap (cancer indication) at 38% compared to Eylea (ocular indications) at 26%; females had a greater proportion of reports for Eylea at 41% compared to Zaltrap at 28%.  The most commonly reported concomitant medications were the same for both genders: 5-fluorouracil, folinic acid, and irinotecan; all other concomitant drugs were reported in 15% or less of the reports.  Alternative explanations for the disproportional increase in males have been considered. First, this increase could be a “statistical artefact”, given the large proportion of reports of DVT in VigiBase with oral contraceptive agents in females. Calculations were therefore made restricting the database to reports from patients aged 45 and above; the increased disproportionality of these events with aflibercept in males remained. Second, this increase could be a reflection of the overall increased baseline risk for DVT in males. However, this baseline increased risk is not reflected in VigiBase data, as there are increased numbers of reports for DVT in females in all age groups, although the difference is smallest in the age group 65 to 74 years (51.2% in females, 47.6% males). Third, a review of the case series did not reveal evidence of an obvious cause for the gender disparity. Two of the most important risk factors for DVT/PE are cancer and advanced age, the former of which was recorded in a greater proportion of males, the latter in a greater proportion of females. The EU labelling for aflibercept notes that gender was found to be a significant covariate for explaining the inter-individual variability of free aflibercept clearance and volume. Males exhibited a 15.5% higher clearance and a 20.6% higher volume of distribution compared to females. However, these differences were considered not to effect exposure due to weight-based dosing, and therefore, no dose modifications based on gender were recommended . Furthermore, within a review of clinical trial data supplied to the US FDA, an exploratory subgroup analysis in a Phase 3 study (VIEW2) was identified which did not reveal any clinically relevant influence of gender on the plasma concentrations of free aflibercept or aflibercept:VEGF complex.11  However, in a literature review, a number of publications were found which describe a gender influence on circulating levels of VEGF. Experimental studies suggest that estrogen may regulate VEGF gene expression and thereby may influence circulating VEGF levels.12-15 Furthermore, there is evidence that females have higher serum VEGF levels than males at all stages of life, including post menopause.16 The overall hypothesis therefore is that females may be at less risk for thromboembolic events with aflibercept therapy as there remains a greater fraction of un-antagonised VEGF during aflibercept therapy ." ;
                                       rdfs:label "Male gender as a potential risk group" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Mechanism_of_Aflibercept
:Mechanism_of_Aflibercept rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Mechanism> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_part_of> :introduction ;
                          mp:references :Ref.1 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Aflibercept is a recombinant protein consisting of specific domains of two human VEGF (vascular endothelial growth factor) receptors, VEGF-R1 and VEGF-R2, fused to an immunoglobulin G1 Fc. It acts as an antagonist that binds and inactivates circulating VEGF and placental growth factor 1; through this mechanism, it inhibits angiogenesis or the growth of new blood vessels." ;
                          rdfs:label "Mechanism of Aflibercept" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Metoprolol
:Metoprolol rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C07AB02" ,
                                                                         "C07AB52" ,
                                                                         "C07BB02" ,
                                                                         "C07BB52" ,
                                                                         "C07CB02" ,
                                                                         "C07FB02" ;
            rdfs:label "Metoprolol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Myopic_choroidal_neovascularisation
:Myopic_choroidal_neovascularisation rdf:type owl:NamedIndividual ,
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "H44.2A9" ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10073709 ;
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Myopic choroidal neovascularisation" ;
                                     rdfs:label "Myopic choroidal neovascularisation" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#NOSTachycardia
:NOSTachycardia rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R00.0" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10043071 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Tachycardia" ;
                rdfs:label "NOS Tachycardia" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#NailsCyanosedPain
:NailsCyanosedPain rdf:type owl:NamedIndividual ,
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "R23.0" ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10011703 ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Cyanosis" ;
                   rdfs:label "Nails cyanosed Pain" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Nebivolol
:Nebivolol rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C07AB12" ,
                                                                        "C07BB12" ,
                                                                        "C07FB12" ;
           rdfs:label "Nebivolol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Neovascularage-relatedMacularDegeneration
:Neovascularage-relatedMacularDegeneration rdf:type owl:NamedIndividual ,
                                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Indication> ;
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "H35.32" ;
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10071129 ;
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Neovascular age-related macular degeneration" ;
                                           rdfs:label "Neovascular age-related macular degeneration" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#OnsetTimeForReport1
:OnsetTimeForReport1 rdf:type owl:NamedIndividual ,
                              <http://www.w3.org/2006/time#DurationDescription> ;
                     <http://www.w3.org/2006/time#nominalPosition> "months" ;
                     <http://www.w3.org/2006/time#numericPosition> 5 ;
                     rdfs:label "Onset time for Report 1" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#OnsetTimeForReport10
:OnsetTimeForReport10 rdf:type owl:NamedIndividual ,
                               <http://www.w3.org/2006/time#DurationDescription> ;
                      <http://www.w3.org/2006/time#nominalPosition> "months" ;
                      <http://www.w3.org/2006/time#numericPosition> 11 ;
                      rdfs:label "Onset time for Report 10" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#OnsetTimeForReport11
:OnsetTimeForReport11 rdf:type owl:NamedIndividual ,
                               <http://www.w3.org/2006/time#DurationDescription> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """Within days of first
dose of aflibercept.
Had received 8 doses
of ranibizumab prior.""" ;
                      rdfs:label "Onset time for Report 11" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#OnsetTimeForReport12
:OnsetTimeForReport12 rdf:type owl:NamedIndividual ,
                               <http://www.w3.org/2006/time#DurationDescription> ;
                      <http://www.w3.org/2006/time#nominalPosition> "months" ;
                      <http://www.w3.org/2006/time#numericPosition> 2 ;
                      rdfs:label "Onset time for Report 12" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#OnsetTimeForReport13
:OnsetTimeForReport13 rdf:type owl:NamedIndividual ,
                               <http://www.w3.org/2006/time#DurationDescription> ;
                      <http://www.w3.org/2006/time#nominalPosition> "days" ;
                      <http://www.w3.org/2006/time#numericPosition> 20 ;
                      rdfs:label "Onset time for Report 13" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#OnsetTimeForReport14
:OnsetTimeForReport14 rdf:type owl:NamedIndividual ,
                               <http://www.w3.org/2006/time#DurationDescription> ;
                      <http://www.w3.org/2006/time#nominalPosition> "months" ;
                      <http://www.w3.org/2006/time#numericPosition> 1 ;
                      rdfs:label "Onset time for Report 14" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#OnsetTimeForReport17
:OnsetTimeForReport17 rdf:type owl:NamedIndividual ,
                               <http://www.w3.org/2006/time#DurationDescription> ;
                      <http://www.w3.org/2006/time#nominalPosition> "months" ;
                      <http://www.w3.org/2006/time#numericPosition> 12 ;
                      rdfs:label "Onset time for Report 17" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#OnsetTimeForReport2
:OnsetTimeForReport2 rdf:type owl:NamedIndividual ,
                              <http://www.w3.org/2006/time#DurationDescription> ;
                     <http://www.w3.org/2006/time#nominalPosition> "months" ;
                     <http://www.w3.org/2006/time#numericPosition> 7 ;
                     rdfs:label "Onset time for Report 2" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#OnsetTimeForReport22
:OnsetTimeForReport22 rdf:type owl:NamedIndividual ,
                               <http://www.w3.org/2006/time#DurationDescription> ;
                      <http://www.w3.org/2006/time#nominalPosition> "days" ;
                      <http://www.w3.org/2006/time#numericPosition> 27 ;
                      rdfs:label "Onset time for Report 22" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#OnsetTimeForReport23
:OnsetTimeForReport23 rdf:type owl:NamedIndividual ,
                               <http://www.w3.org/2006/time#DurationDescription> ;
                      <http://www.w3.org/2006/time#nominalPosition> "days" ;
                      <http://www.w3.org/2006/time#numericPosition> 23 ;
                      rdfs:label "Onset time for Report 23" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#OnsetTimeForReport3
:OnsetTimeForReport3 rdf:type owl:NamedIndividual ,
                              <http://www.w3.org/2006/time#DurationDescription> ;
                     <http://www.w3.org/2006/time#nominalPosition> "months" ;
                     <http://www.w3.org/2006/time#numericPosition> 6 ;
                     rdfs:label "Onset time for Report 3" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#OnsetTimeForReport5
:OnsetTimeForReport5 rdf:type owl:NamedIndividual ,
                              <http://www.w3.org/2006/time#DurationDescription> ;
                     <http://www.w3.org/2006/time#nominalPosition> "months" ;
                     <http://www.w3.org/2006/time#numericPosition> 13 ;
                     rdfs:label "Onset time for Report 5" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#OnsetTimeForReport6
:OnsetTimeForReport6 rdf:type owl:NamedIndividual ,
                              <http://www.w3.org/2006/time#DurationDescription> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """8 months after the first
dose, 1 month after the
last dose.""" ;
                     rdfs:label "Onset time for Report 6" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#OnsetTimeForReport7
:OnsetTimeForReport7 rdf:type owl:NamedIndividual ,
                              <http://www.w3.org/2006/time#DurationDescription> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """13 months after
first dose. 2 months
after last dose.""" ;
                     rdfs:label "Onset time for Report 7" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#OnsetTimeForReport9
:OnsetTimeForReport9 rdf:type owl:NamedIndividual ,
                              <http://www.w3.org/2006/time#DurationDescription> ;
                     <http://www.w3.org/2006/time#nominalPosition> "months" ;
                     <http://www.w3.org/2006/time#numericPosition> 5 ;
                     rdfs:label "Onset time for Report 9" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#OverallReportsForAfliberceptAndDVT
:OverallReportsForAfliberceptAndDVT rdf:type owl:NamedIndividual ,
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> <http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Overall_reports_for_aflibercept_and_DVT_and/or_pulmonary_embolism> ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :DeepVeinThrombosis ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Aflibercept ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 31 ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count_of_men> 19 ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count_of_women> 9 ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_max_age> 89 ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 44 ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                    rdfs:label "Overall reports for aflibercept and DVT" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#OverallReportsForAfliberceptAndPulmonaryEmbolism
:OverallReportsForAfliberceptAndPulmonaryEmbolism rdf:type owl:NamedIndividual ,
                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> <http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Overall_reports_for_aflibercept_and_DVT_and/or_pulmonary_embolism> ;
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :PulmonaryEmbolism ;
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Aflibercept ;
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 60 ;
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count_of_men> 33 ;
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count_of_women> 21 ;
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_max_age> 92 ;
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 25 ;
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                  rdfs:label "Overall reports for aflibercept and pulmonary embolism" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Overall_for_aflibercept_-_deep_vein_thrombosis
:Overall_for_aflibercept_-_deep_vein_thrombosis rdf:type owl:NamedIndividual ,
                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :DeepVeinThrombosis ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Aflibercept ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_creation_date> "31/12/2017" ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> -0.38 ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_number_of_reports> 31 ;
                                                rdfs:label "Overall IC025 for aflibercept - deep vein thrombosis" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Overall_for_aflibercept_-_pulmonary_embolism
:Overall_for_aflibercept_-_pulmonary_embolism rdf:type owl:NamedIndividual ,
                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :PulmonaryEmbolism ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Aflibercept ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_creation_date> "31/12/2017" ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 0.38 ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_number_of_reports> 60 ;
                                              rdfs:label "Overall IC025 for aflibercept - pulmonary embolism" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Paracetamol
:Paracetamol rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N02BE01" ;
             rdfs:label "Paracetamol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Patient1
:Patient1 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 71 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 1" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Patient10
:Patient10 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 90 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
           rdfs:label "Patient 10" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Patient11
:Patient11 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 78 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 11" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Patient12
:Patient12 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 75 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 12" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Patient13
:Patient13 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 92 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 13" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Patient14
:Patient14 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 75 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 14" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Patient15
:Patient15 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 15" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Patient16
:Patient16 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 16" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Patient17
:Patient17 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 87 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 17" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Patient18
:Patient18 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 82 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 18" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Patient19
:Patient19 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 86 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 19" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Patient2
:Patient2 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 74 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 2" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Patient20
:Patient20 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 89 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 20" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Patient21
:Patient21 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 73 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 21" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Patient22
:Patient22 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 83 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 22" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Patient23
:Patient23 rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 72 ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
           rdfs:label "Patient 23" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Patient3
:Patient3 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 72 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 3" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Patient4
:Patient4 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 74 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 4" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Patient5
:Patient5 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 70 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 5" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Patient6
:Patient6 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 78 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 6" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Patient7
:Patient7 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 53 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 7" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Patient8
:Patient8 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 8" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Patient9
:Patient9 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Patient> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_age> 78 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
          rdfs:label "Patient 9" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Perindopril
:Perindopril rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C09AA04" ,
                                                                          "C09BA04" ,
                                                                          "C09BB04" ,
                                                                          "C09BX01" ,
                                                                          "C09BX02" ,
                                                                          "C10BX11" ;
             rdfs:label "Perindopril" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Pharmacokinetics_of_aflibercept_intravitrial_administration
:Pharmacokinetics_of_aflibercept_intravitrial_administration rdf:type owl:NamedIndividual ,
                                                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Mechanism> ;
                                                             mp:references :Ref.1 ;
                                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """In the ocular indications, aflibercept is administered intravitreally as a 2 mg dose, to be repeated every month for three consecutive months, followed by 
every other month.
The product labelling of aflibercept presents data on the pharmacokinetics of intravitreal administration. With a dose of 2 mg per eye, the mean plasma Cmax was 0.02 mcg/mL which was reached within 1 to 3 days, while the aflibercept:VEGF complex concentrations reach a Cmax of 0.186 mcg/mL within 14 to 28 days of a 2 mg dose. Aflibercept did not accumulate in the plasma with repeated intravitreal dosing every 4 weeks""" ;
                                                             rdfs:label "Pharmacokinetics of aflibercept intravitrial administration" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Photosensitivity_reaction
:Photosensitivity_reaction rdf:type owl:NamedIndividual ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "L56.8" ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10034972 ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Photosensitivity reaction" ;
                           rdfs:label "Photosensitivity reaction" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#PoplitealVeinThrombosis
:PoplitealVeinThrombosis rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I82.539" ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10062589 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Popliteal vein thrombosis" ;
                         rdfs:label "Popliteal vein thrombosis" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Posology_and_Pharmacokinetics_of_Aflibercept
:Posology_and_Pharmacokinetics_of_Aflibercept rdf:type owl:NamedIndividual ,
                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Literature_information> ;
                                              mp:references :Ref.1 ,
                                                            :Ref.2 ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "In the ocular indications, aflibercept is administered intravitreally as a 2 mg dose, to be repeated every month for three consecutive months, followed by every other month . In the cancer indications, it is administered intravenously 4 mg per kg of body weight prior to each FOLFIRI treatment cycle (every 2 weeks) .1,2 Free aflibercept is primarily cleared by binding to endogenous VEGF to form a stable, inactive complex. Free aflibercept exhibits a faster (nonlinear) clearance at doses below 2 mg/kg, likely due to the high affinity binding of aflibercept to endogenous VEGF. At higher doses, linear clearance is observed, probably due to nonsaturable biological mechanisms of elimination such as protein catabolism; at such doses, free aflibercept clearance was measured to be approximately 1.0 L/day with a terminal half-life of six days.2" ;
                                              rdfs:label "Posology and Pharmacokinetics of Aflibercept" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Possible_mechanism_behind_VEGF_invovlement_in_thromboembolic_events
:Possible_mechanism_behind_VEGF_invovlement_in_thromboembolic_events rdf:type owl:NamedIndividual ,
                                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect_Mechanism> ;
                                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_part_of> :introduction ;
                                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_class> <http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#VEGF/VEGFR_(Vascular_Endothelial_Growth_Factor)_inhibitors> ;
                                                                     mp:references :Ref.4 ,
                                                                                   :Ref.5 ,
                                                                                   :Ref.6 ,
                                                                                   :Ref.7 ,
                                                                                   :Ref.8 ;
                                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "The mechanism for thromboembolic events by VEGF inhibitors is probably multifactorial, given the number of effects VEGF has on vascular walls and the coagulation system.4 Inhibition of circulating VEGF may diminish the ability of the endothelial cells in the vascular wall to regenerate, thereby allowing any defects that expose procoagulant phospholipids on the luminal plasma membrane or underlying matrix to lead to thrombosis or haemorrhage.5 Furthermore, inhibition of the VEGF decreases production of NO and prostacyclin (PGI2, prostaglandin I2) which can predispose to thromboembolic events.6 Finally, an overproduction of erythropoietin caused by vascular endothelial growth factor inhibition may also increase risk of thrombosis by increasing haematocrit and blood viscosity." ;
                                                                     rdfs:label "Possible mechanism behind VEGF inhibitors involvement  in thromboembolic events" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Potassium
:Potassium rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "B05XA17" ,
                                                                        "C03AB01" ,
                                                                        "C03AB02" ,
                                                                        "C03AB03" ,
                                                                        "C03AB04" ,
                                                                        "C03AB05" ,
                                                                        "C03AB06" ,
                                                                        "C03AB07" ,
                                                                        "C03AB08" ,
                                                                        "C03AB09" ,
                                                                        "C03BB02" ,
                                                                        "C03BB03" ,
                                                                        "C03BB04" ,
                                                                        "C03BB05" ,
                                                                        "C03BB07" ,
                                                                        "C03CB01" ,
                                                                        "C03CB02" ;
           rdfs:label "Potassium" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Pravachol
:Pravachol rdf:type owl:NamedIndividual ,
                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C10AA03 " ;
           rdfs:label "Pravachol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Pravastatin
:Pravastatin rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C10AA03" ,
                                                                          "C10BA03" ,
                                                                          "C10BX02" ;
             rdfs:label "Pravastatin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#PulmonaryEmbolism
:PulmonaryEmbolism rdf:type owl:NamedIndividual ,
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I26" ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10037377 ;
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Pulmonary embolism" ;
                   rdfs:label "Pulmonary embolism" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Pulmonary_embolism_in_USA
:Pulmonary_embolism_in_USA rdf:type owl:NamedIndividual ,
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Statistical_Entity> ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :DeepVeinThrombosis ,
                                                                                                    :PulmonaryEmbolism ;
                           mp:references :Ref.3 ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Of the more than 200,000 people that develop venous thrombosis in that country each year, 50,000 cases are complicated by pulmonary embolism" ;
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/United_States" ;
                           rdfs:label "Pulmonary embolism in USA" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Rabeprazole
:Rabeprazole rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A02BC04" ,
                                                                          "A02BC54" ,
                                                                          "M01AA05" ,
                                                                          "M02AA03" ;
             rdfs:label "Rabeprazole" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Ranibizumab
:Ranibizumab rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "S01LA04" ;
             rdfs:label "Ranibizumab" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Rebecca_E._Chandler
:Rebecca_E._Chandler rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Author> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_affiliation> "Uppsala Monitoring Centre" ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_first_name> "Rebecca" ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_last_name> "Chandler" ;
                     rdfs:label "Rebecca E. Chandler" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Ref.1
:Ref.1 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "European Medicines Agency: Summary of Product Characteristics for aflibercept (Eylea). Available from: http://www.ema.europa.eu/docs/en_GB/ document_library/EPAR__Product_Information / human/002392/WC500135815.pdf. Accessed: 11 January 2018 " ;
       rdfs:label "Ref.1" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Ref.10
:Ref.10 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Nordström M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med. 1992 Aug;232(2):155-60. " ;
        rdfs:label "Ref.10" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Ref.11
:Ref.11 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "https://www.accessdata.fda.gov/drugsatfd a_docs/nda/2011/125387Orig1s000ClinPha rmR.pdf Accessed: 11 January 2018" ;
        rdfs:label "Ref.11" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Ref.12
:Ref.12 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Rubanyi GM, Johns A, Kauser K. Effect of estrogen on endothelial function and angiogenesis. Vascul Pharmacol. 2002;38:89– 98. " ;
        rdfs:label "Ref.12" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Ref.13
:Ref.13 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Albrecht ED, Babischkin JS, Lidor Y, Anderson LD, Udoff LC, Pepe GJ. Effect of estrogen on angiogenesis in co-cultures of human endometrial cells and microvascular endothelial cells. Hum Reprod. 2003;18:2039–47. " ;
        rdfs:label "Ref.13" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Ref.14
:Ref.14 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Garvin S, Nilsson UW, Dabrosin C. Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR- 1, and VEGFR-2 in breast cancer and endothelial cells. Br J Cancer. 2005;93:1005– 10. 15. " ;
        rdfs:label "Ref.14" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Ref.15
:Ref.15 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Kang DH, Yu ES, Yoon KI, Johnson R. The impact of gender on progression of renal disease: potential role of estrogen-mediated vascular endothelial growth factor regulation and vascular protection. Am J Pathol. 2004;164(2):679-88. " ;
        rdfs:label "Ref.15" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Ref.16
:Ref.16 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Malamitsi-Puchner A, Tziotis J, Tsonou A, Protonotariou E, Sarandakou A, Creatsas G. Changes in serum levels of vascular endothelial growth factor in males and females throughout life. Soc Gynecol Investig. 2000 Sep-Oct;7(5):309-12. " ;
        rdfs:label "Ref.16" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Ref.17
:Ref.17 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Avery RL, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014;0:1- 6. " ;
        rdfs:label "Ref.17" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Ref.18
:Ref.18 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Yoshida I, et al. Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudativeagerelatedmaculardegeneration. Graefes Arch Clin Exp Ophthalmol. 2014 Sep;252(9):1483- 9. " ;
        rdfs:label "Ref.18" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Ref.19
:Ref.19 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Wang X, et al. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration. American Journal of Ophthalmology. 2014 Oct;158(4):738-44. " ;
        rdfs:label "Ref.19" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Ref.2
:Ref.2 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "European Medicines Agency: Summary of Product Characteristics for aflibercept (Zaltrap). Available from: http://www.ema.europa.eu/docs/en_GB/ document_library/EPAR__Product_Information / human/002532/WC500139484.pdf Accessed: 11 January 2018 " ;
       rdfs:label "Ref.2" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Ref.20
:Ref.20 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Christoforidis JB, Briley K, Binzel K, Bhatia P, Wei L, Kumar K, Knopp MV. Systemic Biodistribution and Intravitreal Pharmacokinetic Properties of Bevacizumab, Ranibizumab, and Aflibercept in a Nonhuman Primate Model. Invest Ophthalmol Vis Sci. 2017 Nov 1;58(13):5636-45 " ;
        rdfs:label "Ref.20" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Ref.21
:Ref.21 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "http://www.ema.europa.eu/docs/en_GB/docu ment_library/Minutes/2014/11/WC500177868 .pdf Accessed: 11 January 2018 " ;
        rdfs:label "Ref.21" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Ref.22
:Ref.22 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "http://www.ema.europa.eu/docs/en_GB/docu ment_library/Minutes/2016/01/WC500199609 .pdf Accessed: 11 January 2018 " ;
        rdfs:label "Ref.22" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Ref.23
:Ref.23 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Avery RL. What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned? Br J Ophthalmol. 2014 Jun;98 Suppl 1:i7-10. " ;
        rdfs:label "Ref.23" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Ref.24
:Ref.24 rdf:type owl:NamedIndividual ,
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Intravitreal ranibizumab, bevacizumab and aflibercept: thrombosis. Prescrire. No.189. January 2018. 17-19. " ;
        rdfs:label "Ref.24" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Ref.3
:Ref.3 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year populationbased study. Arch Intern Med. 1998 Mar 23;158(6):585-93. " ;
       rdfs:label "Ref.3" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Ref.4
:Ref.4 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007; Jun 18;96(12):1788-95. " ;
       rdfs:label "Ref.4" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Ref.5
:Ref.5 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol. 2003;21:3542 " ;
       rdfs:label "Ref.5" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Ref.6
:Ref.6 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol. 2001;280: C1375–86. " ;
       rdfs:label "Ref.6" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Ref.7
:Ref.7 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002;100:4272–90 " ;
       rdfs:label "Ref.7" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Ref.8
:Ref.8 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Tam BY, Wei K, Rudge JS, Hoffman J, Holash J, etl al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 2006;12:793–800 " ;
       rdfs:label "Ref.8" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Ref.9
:Ref.9 rdf:type owl:NamedIndividual ,
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Bibliographic_reference> ;
       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Roach REJ, Lijfering WM, Rosendaal FR, Cannegiete SC, le Cessie S. Sex Difference in Risk of Second but Not of First Venous Thrombosis: Paradox Explained. Circulation. 2014;129:51-6 " ;
       rdfs:label "Ref.9" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Report1
:Report1 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Deep_vein_thrombosis_leg ,
                                                                                  :PulmonaryEmbolism ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Amlodipine ,
                                                                                    :Candesartan ,
                                                                                    :Fenofibrate ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient1 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Aflibercept ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :OnsetTimeForReport1 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
         rdfs:label "Report 1" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Report10
:Report10 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :PulmonaryEmbolism ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient10 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Aflibercept ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :OnsetTimeForReport10 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 10" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Report11
:Report11 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Air_hunger ,
                                                                                   :Difficulty_breathing_Air ,
                                                                                   :PulmonaryEmbolism ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Atorvastatin ,
                                                                                     :Levothyroxine ,
                                                                                     :Metoprolol ,
                                                                                     :Tiotropium ,
                                                                                     :Zolpidem ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient11 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Aflibercept ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :OnsetTimeForReport11 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 11" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Report12
:Report12 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :PulmonaryEmbolism ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :AcetylsalicylicAcid ,
                                                                                     :Levothyroxine ,
                                                                                     <http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Candesartan_/_Hydrochlorothiazine> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient12 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Aflibercept ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Ranibizumab ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :OnsetTimeForReport12 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovering" ;
          rdfs:label "Report 12" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Report13
:Report13 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :PulmonaryEmbolism ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient13 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Aflibercept ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :OnsetTimeForReport13 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 13" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Report14
:Report14 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :ChestPain ,
                                                                                   :DyspnoeaExertional ,
                                                                                   :Hypertension ,
                                                                                   :Hyperventilation ,
                                                                                   :NOSTachycardia ,
                                                                                   :NailsCyanosedPain ,
                                                                                   :PulmonaryEmbolism ,
                                                                                   :UncontrolledHypertension ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient14 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Aflibercept ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :OnsetTimeForReport14 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "death" ;
          rdfs:label "Report 14" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Report15
:Report15 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :DeepVeinThrombosis ,
                                                                                   :Headache ,
                                                                                   :diabetesMellitus ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient15 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Aflibercept ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 15" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Report16
:Report16 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :PulmonaryEmbolism ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient16 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Aflibercept ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 16" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Report17
:Report17 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :PulmonaryEmbolism ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Bisoprolol ,
                                                                                     :Budesonide ,
                                                                                     :Buprenorphine ,
                                                                                     :Citalopram ,
                                                                                     :FolicAcid ,
                                                                                     :Formoterol ,
                                                                                     :GlycerylTrinitrate ,
                                                                                     :Heparinoid ,
                                                                                     :Hypromellose ,
                                                                                     :Isosorbide_mononitrate ,
                                                                                     :Lactullose ,
                                                                                     :Levothyroxine ,
                                                                                     :Paracetamol ,
                                                                                     :Terbutaline ,
                                                                                     <http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Calcium_carbonate_/_Colecalciferol> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Zolpidem ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient17 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Aflibercept ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :OnsetTimeForReport17 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with sequelae" ;
          rdfs:label "Report 17" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Report18
:Report18 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :PulmonaryEmbolism ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient18 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Aflibercept ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
          rdfs:label "Report 18" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Report19
:Report19 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Photosensitivity_reaction ,
                                                                                   :PulmonaryEmbolism ,
                                                                                   :cornealErosion ,
                                                                                   :eyePain ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Pravachol ,
                                                                                     :Thyroid_therapy ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient19 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Aflibercept ;
          rdfs:label "Report 19" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Report2
:Report2 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Deep_vein_thrombosis_leg ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Atorvastatin ,
                                                                                    :Finasteride ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient2 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Aflibercept ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :OnsetTimeForReport2 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
         rdfs:label "Report 2" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Report20
:Report20 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :DeepVeinThrombosis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient20 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Aflibercept ;
          rdfs:label "Report 20" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Report21
:Report21 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :DeepVeinThrombosis ,
                                                                                   :ThrombophlebitisSuperficial ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient21 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Aflibercept ;
          rdfs:label "Report 21" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Report22
:Report22 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :PulmonaryEmbolism ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :AcetylsalicylicAcid ,
                                                                                     :Candesartan ,
                                                                                     :Doxepin ,
                                                                                     :Estradiol ,
                                                                                     :GlycerylTrinitrate ,
                                                                                     :Paracetamol ,
                                                                                     :Simvastatin ,
                                                                                     <http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Alendronic_acid_/_colecalciferol> ,
                                                                                     <http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Cyanocobalamin_/_Folic_acid_/__pyridoxine> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient22 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Aflibercept ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :OnsetTimeForReport22 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "no recovery" ;
          rdfs:label "Report 22" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Report23
:Report23 rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :PoplitealVeinThrombosis ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient23 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Aflibercept ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_secondary_suspect_drug> :Ranibizumab ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :OnsetTimeForReport23 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
          rdfs:label "Report 23" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Report3
:Report3 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :DeepVeinThrombosis ,
                                                                                  :PulmonaryEmbolism ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient3 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Aflibercept ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :OnsetTimeForReport3 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
         rdfs:label "Report 3" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Report4
:Report4 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :DeepVeinThrombosis ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient4 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Aflibercept ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "no recovery" ;
         rdfs:label "Report 4" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Report5
:Report5 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :DeepVeinThrombosis ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient5 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Aflibercept ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :OnsetTimeForReport5 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "no recovery" ;
         rdfs:label "Report 5" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Report6
:Report6 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Deep_vein_thrombosis_leg ,
                                                                                  :PulmonaryEmbolism ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Allopurinol ,
                                                                                    :Candesartan ,
                                                                                    :EicosapentaenoicAcid ,
                                                                                    :Pravastatin ,
                                                                                    :Rabeprazole ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient6 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Aflibercept ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :OnsetTimeForReport6 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovering" ;
         rdfs:label "Report 6" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Report7
:Report7 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :PulmonaryEmbolism ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_concomitant_drug> :Allopurinol ,
                                                                                    :Doxazosin ,
                                                                                    :Empagliflozin ,
                                                                                    :Furosemide ,
                                                                                    :Nebivolol ,
                                                                                    :Perindopril ,
                                                                                    :Potassium ,
                                                                                    :Simvastatin ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient7 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Aflibercept ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :OnsetTimeForReport7 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "recovery with no further information" ;
         rdfs:label "Report 7" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Report8
:Report8 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :PulmonaryEmbolism ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient8 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Aflibercept ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
         rdfs:label "Report 8" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Report9
:Report9 rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#VigiBase_Report> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :PulmonaryEmbolism ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient9 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_primary_suspect_drug> :Aflibercept ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :OnsetTimeForReport9 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_outcome_after_action> "unknown" ;
         rdfs:label "Report 9" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsFromAustraliaForPulmonaryEmbolism
:ReportsFromAustraliaForPulmonaryEmbolism rdf:type owl:NamedIndividual ,
                                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsForAfliberceptAndPulmonaryEmbolism ;
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 3 ;
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Australia" ;
                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                          rdfs:label "Reports from Australia for pulmonary embolism" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsFromBelgiumForPulmonaryEmbolism
:ReportsFromBelgiumForPulmonaryEmbolism rdf:type owl:NamedIndividual ,
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsForAfliberceptAndPulmonaryEmbolism ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Belgium" ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                        rdfs:label "Reports from Belgium for pulmonary embolism" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsFromCyprusForDVT
:ReportsFromCyprusForDVT rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsForAfliberceptAndDVT ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Cyprus" ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                         rdfs:label "Reports from Cyprus for DVT" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsFromCzechRepublicForPulmonaryEmbolism
:ReportsFromCzechRepublicForPulmonaryEmbolism rdf:type owl:NamedIndividual ,
                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsForAfliberceptAndPulmonaryEmbolism ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Czech_Republic" ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                              rdfs:label "Reports from Czech Republic for pulmonary embolism" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsFromFinlandForPulmonaryEmbolism
:ReportsFromFinlandForPulmonaryEmbolism rdf:type owl:NamedIndividual ,
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsForAfliberceptAndPulmonaryEmbolism ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Finland" ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                        rdfs:label "Reports from Finland for pulmonary embolism" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsFromFranceForPulmonaryEmbolism
:ReportsFromFranceForPulmonaryEmbolism rdf:type owl:NamedIndividual ,
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsForAfliberceptAndPulmonaryEmbolism ;
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/France" ;
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                       rdfs:label "Reports from France for pulmonary embolism" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsFromGermanyForDVT
:ReportsFromGermanyForDVT rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsForAfliberceptAndDVT ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 5 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Germany" ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                          rdfs:label "Reports from Germany for DVT" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsFromGermanyForPulmonaryEmbolism
:ReportsFromGermanyForPulmonaryEmbolism rdf:type owl:NamedIndividual ,
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsForAfliberceptAndPulmonaryEmbolism ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 15 ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Germany" ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                        rdfs:label "Reports from Germany for pulmonary embolism" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsFromGreeceForDVT
:ReportsFromGreeceForDVT rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsForAfliberceptAndDVT ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Greece" ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                         rdfs:label "Reports from Greece for DVT" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsFromGreeceForPulmonaryEmbolism
:ReportsFromGreeceForPulmonaryEmbolism rdf:type owl:NamedIndividual ,
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsForAfliberceptAndPulmonaryEmbolism ;
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Greece" ;
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                       rdfs:label "Reports from Greece for pulmonary embolism" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsFromHungaryForDVT
:ReportsFromHungaryForDVT rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsForAfliberceptAndDVT ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Hungary" ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                          rdfs:label "Reports from Hungary for DVT" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsFromHungaryForPulmonaryEmbolism
:ReportsFromHungaryForPulmonaryEmbolism rdf:type owl:NamedIndividual ,
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsForAfliberceptAndPulmonaryEmbolism ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Hungary" ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                        rdfs:label "Reports from Hungary for pulmonary embolism" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsFromItalyForDVT
:ReportsFromItalyForDVT rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsForAfliberceptAndDVT ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Italy" ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                        rdfs:label "Reports from Italy for DVT" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsFromItalyForPulmonaryEmbolism
:ReportsFromItalyForPulmonaryEmbolism rdf:type owl:NamedIndividual ,
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsForAfliberceptAndPulmonaryEmbolism ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 6 ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Italy" ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                      rdfs:label "Reports from  Italy for pulmonary embolism" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsFromJapanForDVT
:ReportsFromJapanForDVT rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsForAfliberceptAndDVT ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 3 ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Japan" ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                        rdfs:label "Reports from Japan for DVT" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsFromJapanForPulmonaryEmbolism
:ReportsFromJapanForPulmonaryEmbolism rdf:type owl:NamedIndividual ,
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsForAfliberceptAndPulmonaryEmbolism ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Japan" ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                      rdfs:label "Reports from Japan for pulmonary embolism" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsFromSlovakiaForPulmonaryEmbolism
:ReportsFromSlovakiaForPulmonaryEmbolism rdf:type owl:NamedIndividual ,
                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsForAfliberceptAndPulmonaryEmbolism ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 1 ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Slovakia" ;
                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                         rdfs:label "Reports from Slovakia for pulmonary embolism" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsFromSpainForDVT
:ReportsFromSpainForDVT rdf:type owl:NamedIndividual ,
                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsForAfliberceptAndDVT ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 4 ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Spain" ;
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                        rdfs:label "Reports from Spain for DVT" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsFromSpainForPulmonaryEmbolism
:ReportsFromSpainForPulmonaryEmbolism rdf:type owl:NamedIndividual ,
                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsForAfliberceptAndPulmonaryEmbolism ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 4 ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Spain" ;
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                      rdfs:label "Reports from Spain for pulmonary embolism" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsFromSwedenForDVT
:ReportsFromSwedenForDVT rdf:type owl:NamedIndividual ,
                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsForAfliberceptAndDVT ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Sweden" ;
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                         rdfs:label "Reports from Sweden for DVT" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsFromSwedenForPulmonaryEmbolism
:ReportsFromSwedenForPulmonaryEmbolism rdf:type owl:NamedIndividual ,
                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsForAfliberceptAndPulmonaryEmbolism ;
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 5 ;
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Sweden" ;
                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                       rdfs:label "Reports from Sweden for pulmonary embolism" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsFromSwitzerlandForPulmonaryEmbolism
:ReportsFromSwitzerlandForPulmonaryEmbolism rdf:type owl:NamedIndividual ,
                                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsForAfliberceptAndPulmonaryEmbolism ;
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 2 ;
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Switzerland" ;
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                            rdfs:label "Reports from Switzerland for pulmonary embolism" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsFromUKForPulmonaryEmbolism
:ReportsFromUKForPulmonaryEmbolism rdf:type owl:NamedIndividual ,
                                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsForAfliberceptAndPulmonaryEmbolism ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 6 ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/United_Kingdom" ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                   rdfs:label "Reports from UK for pulmonary embolism" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsFromUSAForDVT
:ReportsFromUSAForDVT rdf:type owl:NamedIndividual ,
                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsForAfliberceptAndDVT ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 6 ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/United_States" ;
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                      rdfs:label "Reports from USA for DVT" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsFromUSAForPulmonaryEmbolism
:ReportsFromUSAForPulmonaryEmbolism rdf:type owl:NamedIndividual ,
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsForAfliberceptAndPulmonaryEmbolism ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 9 ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/United_States" ;
                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                    rdfs:label "Reports from USA for pulmonary embolism" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Reports_in_Vigibase
:Reports_in_Vigibase rdf:type owl:NamedIndividual ,
                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> ;
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "The analysis was performed on all reports included in VigiBase, the WHO global database of individual case safety reports (ICSRs), on 31 December 2017 . In a signal detection exercise designed to identify drug-ADR pairs with statistically significant increases in disproportionality only within subgroups, the combination of aflibercept – deep vein thrombosis was found to be disproportionately reported in males compared to females. Upon further investigation, this gender difference was also seen for the combination of aflibercept pulmonary embolism . There was a total of 8,711 individual case safety reports for the substance aflibercept in VigiBase. Thirty-one aflibercept ICSRs reported the PT deep vein thrombosis . Nineteen were male, nine were female and three reports had no gender reported. Twenty-three reports were serious, three were non-serious and five reports had no seriousness reported . Countries from which the reports originated were the USA (6), Germany (5), Sweden (2), Spain (4), Hungary (2), Italy (2), Greece (1), Cyprus (1), Australia (5) and Japan (3). The ages ranged from 44 to 89 years.  The drug-ADR combination of aflibercept - deep vein thrombosis had an overall measure of disproportionality, IC025 - 0.38. However, for females the IC005 is -2.15 while for males it is 0.21.  Sixty aflibercept ICSRs reported the PT pulmonary embolism . Thirty-three were male, 21 were female and six reports had no gender reported. Fifty-seven reports were serious, and three reports had no seriousness reported. Countries from which the reports originated were the USA (9), Germany (15), the UK (6), Sweden (5), Spain (4), Italy (6), Czech Republic (2), Belgium (2), Switzerland (2), Finland (1), France (1), Hungary (1), Greece (1), Slovakia (1), Australia (3) and Japan (1). The age ranged from 25 to 92 years. The same pattern was observed for the drug-ADR combination of aflibercept - pulmonary embolism.  The overall IC025 was 0.38, IC005 -0.55 for females and 1.02 for males." ;
                     rdfs:label "Reports in Vigibase" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Reports_with_intravitreal_formulation_for_ocular_indications
:Reports_with_intravitreal_formulation_for_ocular_indications rdf:type owl:NamedIndividual ,
                                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> <http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Overall_reports_for_aflibercept_and_DVT_and/or_pulmonary_embolism> ;
                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_reported_drug_usage> :Intravitreal_usage ;
                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#time_to_onset> :TimeToOnsetForIntravitrealAdministrationOfAflibercept ;
                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 23 ;
                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count_of_men> 10 ;
                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count_of_women> 13 ;
                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_max_age> 92 ;
                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 53 ;
                                                              rdfs:label "Reports with intravitreal formulation for ocular indications" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReprotsFromAustraliaForDVT
:ReprotsFromAustraliaForDVT rdf:type owl:NamedIndividual ,
                                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> :OverallReportsForAfliberceptAndDVT ;
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 5 ;
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/Australia" ;
                            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                            rdfs:label "Reprots from Australia for DVT" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Simvastatin
:Simvastatin rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A10BH51" ,
                                                                          "C10AA01" ,
                                                                          "C10BA02" ,
                                                                          "C10BA04" ,
                                                                          "C10BX01" ,
                                                                          "C10BX04" ;
             rdfs:label "Simvastatin" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Systemic_effects_of_intravitreal_aflibercept
:Systemic_effects_of_intravitreal_aflibercept rdf:type owl:NamedIndividual ,
                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> ;
                                              mp:references :Ref.1 ,
                                                            :Ref.17 ,
                                                            :Ref.18 ,
                                                            :Ref.19 ,
                                                            :Ref.2 ,
                                                            :Ref.20 ,
                                                            :Ref.21 ,
                                                            :Ref.22 ,
                                                            :Ref.23 ,
                                                            :Ref.24 ;
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Within the total of 91 reports for aflibercept and DVT and/or PE, 23 noted the intravitreal formulation for use in ocular indications. Disproportionality analysis at the indication level did not reveal a statistical signal for DVT with aflibercept. However, clinical review of the case series, as well as a review of the literature, support the potential for a causal association. Ten reports concerned males, 13 females. The ages ranged from 53 to 92; no age was provided in three reports. Time to onset was provided in 16 reports and ranged from days up to 13 months. Arguments against a causal association with aflibercept could be the increased baseline risk in the specific population receiving this drug for this indication: elderly persons with a potentially largely sedentary lifestyle secondary to visual difficulties. However, the cases included in the case series demonstrate geographical spread and consistency in aflibercept being the single suspected agent even months after initial administration. The product labelling of aflibercept presents data on the pharmacokinetics of intravitreal administration. With a dose of 2 mg per eye, the mean plasma Cmax was 0.02 mcg/mL which was reached within 1 to 3 days, while the aflibercept:VEGF complex concentrations reach a Cmax of 0.186 mcg/mL within 14 to 28 days of a 2 mg dose. Aflibercept did not accumulate in the plasma with repeated intravitreal dosing every 4 weeks.1 For comparison, the dosing used in the cancer indication (4 mg/kg every 2 weeks) results in an excess of circulating free aflibercept compared to VEGF-bound aflibercept, and that steady states levels of free aflibercept concentration are reached by the second cycle.2 Based on these results, the risk for systemic adverse events, such as arterial and venous thromboembolism, has been estimated to be low.1 Multiple publications since the time of licensure, however, suggest that systemic exposure of aflibercept after intravitreal use of aflibercept is not theoretical. Studies have examined VEGF serum levels following intravitreal anti-VEGF injection and have reported longer duration and more VEGF suppression in the serum after aflibercept compared to another anti-VEGF agent, ranibizumab.17-19 A more recent publication using radiolabelled anti-VEGF agents in non-human primates to investigate intravitreal pharmacokinetic properties and systemic biodistribution revealed aflibercept to have an intravitreal half-life of 2.44 days and to be detectable throughout the body until day 21.20 A signal of higher systemic exposure after intravitreal injection of aflibercept compared to ranibizumab was identified by the EMA in October 2014. The Pharmacovigilance Risk Assessment Committee (PRAC) noted that, during the clinical development for the intravitreal preparation of aflibercept, concerns were raised on its potential role in the development of systemic arterial thromboembolic events, especially cerebrovascular events and transient ischemic attack (TIA). At the time of licensure, MAH had committed in their Risk Management Plan to conduct a post-authorisation study addressing this risk.21 Although the PRAC initially agreed that the signal should be further investigated, minutes from a PRAC meeting in November 2015 note that, after analysis of data by the MAH, there remained no clinically relevant safety signal and the originally planned PASS study, (Long-term Investigation and Risk Benefit analysis of the Real-life utilisation of Aflibercept in macular disease, or LIBRA), was no longer required.22 In contrast to the EMA decision, Avery argues in his paper “What is the evidence for systemic effects of intravitreal anti-AGEF agents, and should we be concerned?” that because numerous studies show reduced systemic VEGF levels after intravitreal injections and individual trials were underpowered to detect statistically significant differences, analyses of large populations will be critical to identify if there is a systemic risk to these intravitreal agents. Also, he emphasized the importance of identification of vulnerable subgroups: “There may be subsets of patients…who may be at increased risk after intravitreal anti-VEGF injection, but further studies are required to evaluate this potential risk.”23 As further support to this hypothesis, the authors of Prescrire recently issued a review of published meta-analyses and concluded that there is probably a two-fold increased risk of arterial or venous thrombosis with use of intravitreal anti-VEGF administration.24" ;
                                              rdfs:label "Systemic effects of intravitreal aflibercept" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Terbutaline
:Terbutaline rdf:type owl:NamedIndividual ,
                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "R03CC03" ;
             rdfs:label "Terbutaline" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#The_annual_incidence_of_DVT_in_the_USA
:The_annual_incidence_of_DVT_in_the_USA rdf:type owl:NamedIndividual ,
                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Incidence> ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :DeepVeinThrombosis ;
                                        mp:referencedBy :Ref.3 ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "80 cases per 100,000." ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_value> 0.00008 ;
                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_country> "http://dbpedia.org/resource/United_States" ;
                                        rdfs:label "The annual incidence of DVT in the USA" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ThrombophlebitisSuperficial
:ThrombophlebitisSuperficial rdf:type owl:NamedIndividual ,
                                      <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I80.0" ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10043595 ;
                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Thrombophlebitis superficial" ;
                             rdfs:label "Thrombophlebitis superficial" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Thyroid_therapy
:Thyroid_therapy rdf:type owl:NamedIndividual ,
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "H03" ;
                 rdfs:label "Thyroid therapy" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#TimeToOnsetForIntravitrealAdministrationOfAflibercept
:TimeToOnsetForIntravitrealAdministrationOfAflibercept rdf:type owl:NamedIndividual ,
                                                                <http://www.w3.org/2006/time#DurationDescription> ;
                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "ranged from days up to 13 months." ;
                                                       rdfs:label "Time to onset for intravitreal administration of aflibercept" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Tiotropium
:Tiotropium rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "R03AL06" ,
                                                                         "R03BB04" ,
                                                                         "R03BB54" ;
            rdfs:label "Tiotropium" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#UncontrolledHypertension
:UncontrolledHypertension rdf:type owl:NamedIndividual ,
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "I10 " ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10066860 ;
                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Uncontrolled hypertension" ;
                          rdfs:label "Uncontrolled Hypertension" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Uppsala_Monitoring_Centre
:Uppsala_Monitoring_Centre rdf:type owl:NamedIndividual ,
                                    <http://www.w3.org/ns/prov#Organization> ;
                           rdfs:label "Uppsala Monitoring Centre" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Yasunori_Aoki
:Yasunori_Aoki rdf:type owl:NamedIndividual ,
                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Author> ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_affiliation> "Uppsala Monitoring Centre" ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_first_name> "Yasunori" ;
               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_last_name> "Aoki" ;
               rdfs:label "Yasunori Aoki" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Zolpidem
:Zolpidem rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "N05CF02" ;
          rdfs:label "Zolpidem" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#conclusion
:conclusion rdf:type owl:NamedIndividual ,
                     <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Conclusion> ;
            <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Within this signal assessment we have used statistical signal detection methodology to prioritise sub-populations at potential risk for further review. Clinical assessment of the cases, pharmacokinetic data, as well as published literature support hypotheses that patients receiving aflibercept in the intravitreal indication, as well as patients who are men are at increased risk of deep vein thrombosis and pulmonary embolism. We hope that further development of such methodologies and identification of signals such as these usher in a new era of “precision pharmacovigilance” with a goal to achieve more finely tuned benefit/risk assessments at the level of the individual patient." ;
            rdfs:label "conclusion" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#cornealErosion
:cornealErosion rdf:type owl:NamedIndividual ,
                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "H18.839" ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10011013 ;
                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Corneal erosion" ;
                rdfs:label "corneal erosion" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#diabetesMellitus
:diabetesMellitus rdf:type owl:NamedIndividual ,
                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "E11 " ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10012601 ;
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Diabetes mellitus" ;
                  rdfs:label "diabetes mellitus" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#eyePain
:eyePain rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Adverse_Effect> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ICD_code> "H57.10" ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_code> 10015958 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_MedDRA_prefered_term> "Eye pain" ;
         rdfs:label "eye pain" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#introduction
:introduction rdf:type owl:NamedIndividual ,
                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Introduction> ;
              mp:references :Ref.1 ,
                            :Ref.2 ,
                            :Ref.3 ,
                            :Ref.4 ,
                            :Ref.5 ,
                            :Ref.6 ,
                            :Ref.7 ,
                            :Ref.8 ;
              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Aflibercept is a recombinant protein consisting of specific domains of two human VEGF (vascular endothelial growth factor) receptors, VEGF-R1 and VEGF-R2, fused to an immunoglobulin G1 Fc. It acts as an antagonist that binds and inactivates circulating VEGF and placental growth factor 1; through this mechanism, it inhibits angiogenesis or the growth of new blood vessels.  Under the trade name Eylea, aflibercept is licensed for use in a number of ocular conditions, including neovascular (wet) age-related macular degeneration (AMD), macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), diabetic macular oedema (DME), and myopic choroidal neovascularisation.1 Under the trade name Zaltrap, it is licensed for use against metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy. 2 Deep venous thrombosis (DVT) is the formation of a blood clot, or thrombus, in one of the deep veins of the body, most commonly in veins of the lower extremities. The mechanism of thrombus formation typically involves a combination of decreased blood flow, injury to the blood vessel wall (endothelium), and an increased tendency to clot. The annual incidence of DVT in the USA has been estimated to be 80 cases per 100,000. Of the more than 200,000 people that develop venous thrombosis in that country each year, 50,000 cases are complicated by pulmonary embolism.3 Deep venous thrombosis usually affects individuals older than 40 years, with increasing incidence with age . Arterial and venous thromboembolic events are both included in the product label for aflibercept for its use in the cancer indication. In the label for its use in ocular indications, only a theoretical risk of arterial thromboembolic events is mentioned.1,2WHO Pharmaceuticals Newsletter No. 6, 2018 • 13 Signal  The mechanism for thromboembolic events by VEGF inhibitors is probably multifactorial, given the number of effects VEGF has on vascular walls and the coagulation system.4 Inhibition of circulating VEGF may diminish the ability of the endothelial cells in the vascular wall to regenerate, thereby allowing any defects that expose procoagulant phospholipids on the luminal plasma membrane or underlying matrix to lead to thrombosis or haemorrhage.5 Furthermore, inhibition of the VEGF decreases production of NO and prostacyclin (PGI2, prostaglandin I2) which can predispose to thromboembolic events.6 Finally, an overproduction of erythropoietin caused by vascular endothelial growth factor inhibition may also increase risk of thrombosis by increasing haematocrit and blood viscosity. 7-8 This signal assessment aims to present evidence that support two hypotheses regarding the association between aflibercept and deep venous thrombosis / pulmonary embolism: 1) male gender may be a potential risk group for deep venous thrombosis / pulmonary embolism with the use of aflibercept, 2) intravitreal use can have systemic effects." ;
              rdfs:label "introduction" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#literature_data_regarding_VEGF_and_estrogen
:literature_data_regarding_VEGF_and_estrogen rdf:type owl:NamedIndividual ,
                                                      <http://purl.obolibrary.org/obo/OAE_0001197> ;
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_class> <http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#VEGF/VEGFR_(Vascular_Endothelial_Growth_Factor)_inhibitors> ;
                                             mp:references :Ref.12 ,
                                                           :Ref.13 ,
                                                           :Ref.14 ,
                                                           :Ref.15 ,
                                                           :Ref.16 ;
                                             <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """\"However, in a literature review, a number of
publications were found which describe a gender
influence on circulating levels of VEGF. Experimental studies suggest that estrogen may
regulate VEGF gene expression and thereby may
influence circulating VEGF levels.12-15 Furthermore,
there is evidence that females have higher serum
VEGF levels than males at all stages of life,
including post menopause.16 The overall hypothesis
therefore is that females may be at less risk for
thromboembolic events with aflibercept therapy as
there remains a greater fraction of un-antagonised
VEGF during aflibercept therapy\"""" ;
                                             rdfs:label "literature data regarding VEGF" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#oneMonthIntervalBetweenAdministrationsFor3ConsecutiveMonths
:oneMonthIntervalBetweenAdministrationsFor3ConsecutiveMonths rdf:type owl:NamedIndividual ,
                                                                      <http://www.w3.org/2006/time#DurationDescription> ;
                                                             <http://www.w3.org/2006/time#months> 1 ;
                                                             rdfs:label "one month interval between administrations for 3 consecutive months" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#pvSignal
:pvSignal rdf:type owl:NamedIndividual ,
                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Signal> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element> :Deep_Vein_Thrombosis ,
                                                                                      :Male_gender_as_a_potential_risk_group ,
                                                                                      :Reports_in_Vigibase ,
                                                                                      :Systemic_effects_of_intravitreal_aflibercept ,
                                                                                      :conclusion ,
                                                                                      :introduction ,
                                                                                      :summary ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_supported_by_individual_case_report> :Report1 ,
                                                                                                 :Report10 ,
                                                                                                 :Report11 ,
                                                                                                 :Report12 ,
                                                                                                 :Report13 ,
                                                                                                 :Report14 ,
                                                                                                 :Report15 ,
                                                                                                 :Report16 ,
                                                                                                 :Report17 ,
                                                                                                 :Report18 ,
                                                                                                 :Report19 ,
                                                                                                 :Report2 ,
                                                                                                 :Report20 ,
                                                                                                 :Report21 ,
                                                                                                 :Report22 ,
                                                                                                 :Report23 ,
                                                                                                 :Report3 ,
                                                                                                 :Report4 ,
                                                                                                 :Report5 ,
                                                                                                 :Report6 ,
                                                                                                 :Report7 ,
                                                                                                 :Report8 ,
                                                                                                 :Report9 ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_supported_by_statistical_entity> :IC005_for_aflibercept_and_DVT_for_females ,
                                                                                             :IC005_for_aflibercept_and_DVT_for_males ,
                                                                                             :IC005_for_aflibercept_and_pulmonary_embolism_for_females ,
                                                                                             :IC005_for_aflibercept_and_pulmonary_embolism_for_males ,
                                                                                             :OverallReportsForAfliberceptAndDVT ,
                                                                                             :OverallReportsForAfliberceptAndPulmonaryEmbolism ,
                                                                                             :Overall_for_aflibercept_-_deep_vein_thrombosis ,
                                                                                             :Overall_for_aflibercept_-_pulmonary_embolism ,
                                                                                             :Pulmonary_embolism_in_USA ,
                                                                                             :ReportsFromAustraliaForPulmonaryEmbolism ,
                                                                                             :ReportsFromBelgiumForPulmonaryEmbolism ,
                                                                                             :ReportsFromCyprusForDVT ,
                                                                                             :ReportsFromCzechRepublicForPulmonaryEmbolism ,
                                                                                             :ReportsFromFinlandForPulmonaryEmbolism ,
                                                                                             :ReportsFromFranceForPulmonaryEmbolism ,
                                                                                             :ReportsFromGermanyForDVT ,
                                                                                             :ReportsFromGermanyForPulmonaryEmbolism ,
                                                                                             :ReportsFromGreeceForDVT ,
                                                                                             :ReportsFromGreeceForPulmonaryEmbolism ,
                                                                                             :ReportsFromHungaryForDVT ,
                                                                                             :ReportsFromHungaryForPulmonaryEmbolism ,
                                                                                             :ReportsFromItalyForDVT ,
                                                                                             :ReportsFromItalyForPulmonaryEmbolism ,
                                                                                             :ReportsFromJapanForDVT ,
                                                                                             :ReportsFromJapanForPulmonaryEmbolism ,
                                                                                             :ReportsFromSlovakiaForPulmonaryEmbolism ,
                                                                                             :ReportsFromSpainForDVT ,
                                                                                             :ReportsFromSpainForPulmonaryEmbolism ,
                                                                                             :ReportsFromSwedenForDVT ,
                                                                                             :ReportsFromSwedenForPulmonaryEmbolism ,
                                                                                             :ReportsFromSwitzerlandForPulmonaryEmbolism ,
                                                                                             :ReportsFromUKForPulmonaryEmbolism ,
                                                                                             :ReportsFromUSAForDVT ,
                                                                                             :ReportsFromUSAForPulmonaryEmbolism ,
                                                                                             :Reports_with_intravitreal_formulation_for_ocular_indications ,
                                                                                             :ReprotsFromAustraliaForDVT ,
                                                                                             :The_annual_incidence_of_DVT_in_the_USA ,
                                                                                             <http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Overall_reports_for_aflibercept_and_DVT_and/or_pulmonary_embolism> ,
                                                                                             <http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsOfDeepVeinThrombosisand/orPulmonaryEmbolismInMen> ,
                                                                                             <http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsOfDeepVeinThrombosisand/orPulmonaryEmbolismInWomen> ,
                                                                                             <http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsOfDeepVeinThrombosisand/orPulmonaryEmbolismInmen-agesBetween45-74> ,
                                                                                             <http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Reports_of_deep_vein_thrombosis_and/or_pulmonary_embolism_in_women_over_65_years_old> ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :DeepVeinThrombosis ,
                                                                                   :PulmonaryEmbolism ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Aflibercept ;
          mp:supportedByData :Aflibercept_product_label ,
                             :Clinical_trial_report_for_Aflibercept ,
                             :EU_labelling ,
                             :Epidemiological__studies_regarding_gender-specific_baseline_risk_for__DVT ,
                             :literature_data_regarding_VEGF_and_estrogen ,
                             :review_of_published_meta-analyses ,
                             :studies ;
          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#initially_identified_on> "01/12/2018" ;
          rdfs:label "pv signal" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#review_of_published_meta-analyses
:review_of_published_meta-analyses rdf:type owl:NamedIndividual ,
                                            <http://purl.obolibrary.org/obo/OAE_0001197> ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :Arterial_thrombosis ,
                                                                                                            :DeepVeinThrombosis ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_class> <http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#VEGF/VEGFR_(Vascular_Endothelial_Growth_Factor)_inhibitors> ;
                                   mp:references :Ref.24 ;
                                   <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "As further support to this hypothesis, the authors of Prescrire recently issued a review of published meta-analyses and concluded that there is probably a two-fold increased risk of arterial or venous thrombosis with use of intravitreal anti-VEGF administration.24" ;
                                   rdfs:label "review of published meta-analyses" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#studies
:studies rdf:type owl:NamedIndividual ,
                  <http://purl.obolibrary.org/obo/OAE_0001197> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_class> <http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#VEGF/VEGFR_(Vascular_Endothelial_Growth_Factor)_inhibitors> ;
         mp:references :Ref.17 ,
                       :Ref.18 ,
                       :Ref.19 ,
                       :Ref.20 ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Studies have examined VEGF serum levels following intravitreal anti-VEGF injection and have reported longer duration and more VEGF suppression in the serum after aflibercept compared to another anti-VEGF agent, ranibizumab.17-19 A more recent publication using radiolabelled anti-VEGF agents in non-human primates to investigate intravitreal pharmacokinetic properties and systemic biodistribution revealed aflibercept to have an intravitreal half-life of 2.44 days and to be detectable throughout the body until day 21" ;
         rdfs:label "Studies examining VEGF serum levels following intravitreal injection" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#summary
:summary rdf:type owl:NamedIndividual ,
                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Summary> ;
         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "A novel approach to signal detection screening was recently investigated at UMC. Designed to be sensitive to disproportionality between subpopulations, the screening highlighted a significant increased reporting of deep vein thrombosis with the use of aflibercept in males compared to females. Aflibercept is an antagonist of VEGF (vascular endothelial growth factor) receptors and through this mechanism inhibits angiogenesis or the growth of new blood vessels. Aflibercept is used in the treatment of a number of ocular conditions with an ocular preparation called Eylea and in the treatment of metastatic colorectal cancer with an intravenous preparation called Zaltrap. Clinical assessment of the combination of aflibercept and deep vein thrombosis included review of deep vein thrombosis and pulmonary embolism in both indications of use for aflibercept as well as a closer investigation of potential gender related factors which could support a hypothesis of an increased risk for these events in men." ;
         rdfs:label "summary" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#twoWeeksIntervalsBetweenAdministration
:twoWeeksIntervalsBetweenAdministration rdf:type owl:NamedIndividual ,
                                                 <http://www.w3.org/2006/time#DurationDescription> ;
                                        <http://www.w3.org/2006/time#weeks> 2 ;
                                        rdfs:label "two weeks intervals between administration" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#1
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#1> rdf:type owl:NamedIndividual ,
                                                                                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient23 ;
                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Spontaneous report." ;
                                                                                                        rdfs:label "Case Info 23" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#10
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#10> rdf:type owl:NamedIndividual ,
                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient10 ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Spontaneous report. Treated with warfarin." ;
                                                                                                         rdfs:label "Case Info 10" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#11
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#11> rdf:type owl:NamedIndividual ,
                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient11 ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Spontaneous report." ;
                                                                                                         rdfs:label "Case Info 11" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#12
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#12> rdf:type owl:NamedIndividual ,
                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Ref.12 ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Spontaneous report." ;
                                                                                                         rdfs:label "Case Info 12" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#13
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#13> rdf:type owl:NamedIndividual ,
                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient13 ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Spontaneous report." ;
                                                                                                         rdfs:label "Case Info 13" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#14
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#14> rdf:type owl:NamedIndividual ,
                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient14 ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Spontaneous report. Sonography of carotid, subclavian and coronary vessels with only evidence of mild stenosis." ;
                                                                                                         rdfs:label "Case Info 14" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#15
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#15> rdf:type owl:NamedIndividual ,
                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient15 ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Spontaneous report." ;
                                                                                                         rdfs:label "Case Info 15" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#16
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#16> rdf:type owl:NamedIndividual ,
                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient16 ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Spontaneous report." ;
                                                                                                         rdfs:label "Case Info 16" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#17
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#17> rdf:type owl:NamedIndividual ,
                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient17 ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Spontaneous report." ;
                                                                                                         rdfs:label "Case Info 17" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#18
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#18> rdf:type owl:NamedIndividual ,
                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient18 ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Spontaneous report." ;
                                                                                                         rdfs:label "Case Info 18" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#19
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#19> rdf:type owl:NamedIndividual ,
                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient19 ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Spontaneous report." ;
                                                                                                         rdfs:label "Case Info 19" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#2
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#2> rdf:type owl:NamedIndividual ,
                                                                                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient2 ;
                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Received a total of 4 doses. Treated with Fragmin and then Xarelto" ;
                                                                                                        rdfs:label "Case Info 2" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#2MonthIntervalBetweenAdministrations
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#2MonthIntervalBetweenAdministrations> rdf:type owl:NamedIndividual ,
                                                                                                                                                    <http://www.w3.org/2006/time#DurationDescription> ;
                                                                                                                                           rdfs:label "2 month interval between administrations" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#20
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#20> rdf:type owl:NamedIndividual ,
                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient20 ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Spontaneous report." ;
                                                                                                         rdfs:label "Case Info 20" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#21
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#21> rdf:type owl:NamedIndividual ,
                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient21 ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Spontaneous report." ;
                                                                                                         rdfs:label "Case Info 21" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#22
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#22> rdf:type owl:NamedIndividual ,
                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient22 ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Spontaneous report." ;
                                                                                                         rdfs:label "Case Info 22" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#23
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#23> rdf:type owl:NamedIndividual ,
                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient1 ;
                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Received a total of 4 doses" ;
                                                                                                         rdfs:label "Case Info 1" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#4
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#4> rdf:type owl:NamedIndividual ,
                                                                                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient4 ;
                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Spontaneous report" ;
                                                                                                        rdfs:label "Case Info 4" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#6
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#6> rdf:type owl:NamedIndividual ,
                                                                                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient6 ;
                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Spontaneous report. Received a total of 5 doses" ;
                                                                                                        rdfs:label "Case Info 6" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#7
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#7> rdf:type owl:NamedIndividual ,
                                                                                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient7 ;
                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Spontaneous report. Received a total of 4 doses. Placed on long term anticoagulant therapy." ;
                                                                                                        rdfs:label "Case Info 7" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#8
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#8> rdf:type owl:NamedIndividual ,
                                                                                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient8 ;
                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Spontaneous report." ;
                                                                                                        rdfs:label "Case Info 8" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#9
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#9> rdf:type owl:NamedIndividual ,
                                                                                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Case_Report_Information> ;
                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_patient> :Patient9 ;
                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Spontaneous report. Had been treated with anti-VEGF agents since 2013. Previously with Avastin. Discontinued treatment" ;
                                                                                                        rdfs:label "Case Info 9" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Aflibercept_and_deep_vein_thrombosis/pulmonary_embolism
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Aflibercept_and_deep_vein_thrombosis/pulmonary_embolism> rdf:type owl:NamedIndividual ,
                                                                                                                                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Pharmacovigilance_Signal_Report> ;
                                                                                                                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_author> :Lovisa_Sandberg ,
                                                                                                                                                                                                                               :Rebecca_E._Chandler ,
                                                                                                                                                                                                                               :Yasunori_Aoki ;
                                                                                                                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_signal> :pvSignal ;
                                                                                                                                                              mp:publishedBy :Uppsala_Monitoring_Centre ;
                                                                                                                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_creation_date> "01/12/2018"^^xsd:date ;
                                                                                                                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_overall_conclusion> "causal association most probable" ;
                                                                                                                                                              rdfs:label "Aflibercept and deep vein thrombosis/pulmonary embolism" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Alendronic_acid_/_colecalciferol
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Alendronic_acid_/_colecalciferol> rdf:type owl:NamedIndividual ,
                                                                                                                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                                                                                                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A11CC05" ,
                                                                                                                                                                                                    "A11CC55" ,
                                                                                                                                                                                                    "M05BA04" ,
                                                                                                                                                                                                    "M05BB03" ,
                                                                                                                                                                                                    "M05BB04" ,
                                                                                                                                                                                                    "M05BB05" ,
                                                                                                                                                                                                    "M05BB06" ,
                                                                                                                                                                                                    "M05BB07" ,
                                                                                                                                                                                                    "M05BB08" ,
                                                                                                                                                                                                    "M05BB09" ,
                                                                                                                                                                                                    "M05BX53" ;
                                                                                                                                       rdfs:label "Alendronic acid / colecalciferol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Calcium_carbonate_/_Colecalciferol
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Calcium_carbonate_/_Colecalciferol> rdf:type owl:NamedIndividual ,
                                                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                                                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A02AC01" ,
                                                                                                                                                                                                      "A11CC05" ,
                                                                                                                                                                                                      "A11CC55" ,
                                                                                                                                                                                                      "M05BB03" ,
                                                                                                                                                                                                      "M05BB04" ,
                                                                                                                                                                                                      "M05BB05" ,
                                                                                                                                                                                                      "M05BB07" ,
                                                                                                                                                                                                      "M05BB08" ,
                                                                                                                                                                                                      "M05BB09" ,
                                                                                                                                                                                                      "M05BX53" ;
                                                                                                                                         rdfs:label "Calcium carbonate / Colecalciferol" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Candesartan_/_Hydrochlorothiazine
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Candesartan_/_Hydrochlorothiazine> rdf:type owl:NamedIndividual ,
                                                                                                                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                                                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "C03AA03" ,
                                                                                                                                                                                                     "C09CA06" ,
                                                                                                                                                                                                     "C09DA06" ;
                                                                                                                                        rdfs:label "Candesartan / Hydrochlorothiazide" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Cyanocobalamin_/_Folic_acid_/__pyridoxine
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Cyanocobalamin_/_Folic_acid_/__pyridoxine> rdf:type owl:NamedIndividual ,
                                                                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Drug> ;
                                                                                                                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "A11HA02" ,
                                                                                                                                                                                                             "B03AE01" ,
                                                                                                                                                                                                             "B03AE02" ,
                                                                                                                                                                                                             "B03BA01" ,
                                                                                                                                                                                                             "B03BA51" ,
                                                                                                                                                                                                             "B03BB01" ,
                                                                                                                                                                                                             "B03BB51" ;
                                                                                                                                                rdfs:label "Cyanocobalamin / Folic acid /  pyridoxine" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Overall_reports_for_aflibercept_and_DVT_and/or_pulmonary_embolism
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Overall_reports_for_aflibercept_and_DVT_and/or_pulmonary_embolism> rdf:type owl:NamedIndividual ,
                                                                                                                                                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                                                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :DeepVeinThrombosis ,
                                                                                                                                                                                                                                                 :PulmonaryEmbolism ;
                                                                                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Aflibercept ;
                                                                                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 91 ;
                                                                                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                                                                                                                                        rdfs:label "Overall reports for aflibercept and DVT and/or pulmonary embolism" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Pharmacokinetics_of_aflibercept_(IV)_for_cancer_patients
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Pharmacokinetics_of_aflibercept_(IV)_for_cancer_patients> rdf:type owl:NamedIndividual ,
                                                                                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Mechanism> ;
                                                                                                                                                               mp:references :Ref.2 ;
                                                                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> """In the cancer indications, it is administered intravenously 4 mg per kg of body weight prior to each FOLFIRI treatment cycle (every 2 weeks).
Free aflibercept is primarily cleared by binding to endogenous VEGF to form a stable, inactive complex. Free aflibercept exhibits a faster (nonlinear) clearance at doses below 2 mg/kg, likely due to the high affinity binding of aflibercept to endogenous VEGF. At higher doses, linear clearance is observed, probably due to nonsaturable biological mechanisms of elimination such as protein catabolism; at such doses, free aflibercept clearance was measured to be approximately 1.0 L/day with a terminal half-life of six days.
For comparison, the dosing used in the cancer indication (4 mg/kg every 2 weeks) results in an excess of circulating free aflibercept compared to VEGF-bound aflibercept, and that steady states levels of free aflibercept concentration are reached by the second cycle.2""" ;
                                                                                                                                                               rdfs:label "Pharmacokinetics of aflibercept (IV) for cancer patients" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsOfDeepVeinThrombosisand/orPulmonaryEmbolismInMen
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsOfDeepVeinThrombosisand/orPulmonaryEmbolismInMen> rdf:type owl:NamedIndividual ,
                                                                                                                                                                       <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                                                                                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :DeepVeinThrombosis ,
                                                                                                                                                                                                                                       :PulmonaryEmbolism ;
                                                                                                                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Aflibercept ;
                                                                                                                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 46 ;
                                                                                                                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count_of_men> 46 ;
                                                                                                                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "male" ;
                                                                                                                                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                                                                                                                              rdfs:label "Reports of deep vein thrombosis and/or pulmonary embolism in men" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsOfDeepVeinThrombosisand/orPulmonaryEmbolismInWomen
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsOfDeepVeinThrombosisand/orPulmonaryEmbolismInWomen> rdf:type owl:NamedIndividual ,
                                                                                                                                                                         <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                                                                                                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_adverse_effect> :DeepVeinThrombosis ,
                                                                                                                                                                                                                                         :PulmonaryEmbolism ;
                                                                                                                                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_drug> :Aflibercept ;
                                                                                                                                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 28 ;
                                                                                                                                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count_of_women> 28 ;
                                                                                                                                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_gender> "female" ;
                                                                                                                                                                <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                                                                                                                                rdfs:label "Reports of deep vein thrombosis and/or pulmonary embolism in women" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsOfDeepVeinThrombosisand/orPulmonaryEmbolismInmen-agesBetween45-74
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsOfDeepVeinThrombosisand/orPulmonaryEmbolismInmen-agesBetween45-74> rdf:type owl:NamedIndividual ,
                                                                                                                                                                                        <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                                                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> <http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsOfDeepVeinThrombosisand/orPulmonaryEmbolismInMen> ;
                                                                                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 31 ;
                                                                                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count_of_men> 31 ;
                                                                                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_max_age> 74 ;
                                                                                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 45 ;
                                                                                                                                                                               <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                                                                                                                                               rdfs:label "Reports of deep vein thrombosis and/or pulmonary embolism in men-ages between 45-74" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Reports_of_deep_vein_thrombosis_and/or_pulmonary_embolism_in_women_over_65_years_old
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Reports_of_deep_vein_thrombosis_and/or_pulmonary_embolism_in_women_over_65_years_old> rdf:type owl:NamedIndividual ,
                                                                                                                                                                                                    <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Reports_group> ;
                                                                                                                                                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#is_subgroup_of> <http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#ReportsOfDeepVeinThrombosisand/orPulmonaryEmbolismInWomen> ;
                                                                                                                                                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count> 18 ;
                                                                                                                                                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_count_of_women> 18 ;
                                                                                                                                                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_min_age> 65 ;
                                                                                                                                                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#refers_to_database> "WHO Vigibase" ;
                                                                                                                                                                                           rdfs:label "Reports of deep vein thrombosis and/or pulmonary embolism in women over 65 years old" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Response_from_Bayer_on_the_intravitreal_formulation_of_aflibercept_(Eylea®)
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#Response_from_Bayer_on_the_intravitreal_formulation_of_aflibercept_(Eylea®)> rdf:type owl:NamedIndividual ,
                                                                                                                                                                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Response_to_Pharmacovigilance_Signal_Report> ;
                                                                                                                                                                                  <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_content> "Sanofi was invited to comment on the intravenous formulation of aflibercept with systemic effect but declined the invitation. Thus, the following text, submitted by Bayer, only addresses the intravitreal formulation To date, venous thromboembolic events (VTEs) including deep vein thrombosis (DVT) and pulmonary embolism (PE) have not been established as an identified risk with local intravitreal (IVT) use of 2mg aflibercept (Eylea®) in ophthalmologic indications.1 VTEs have been associated and are considered an identified risk with systemically administered anti-VEGFs with significantly higher systemic exposure for cancer treatment, including intravenously administered ziv-aflibercept (Zaltrap®, dosed with 4mg/kg BW). The systemic exposure of pharmacologically active aflibercept is 3000-fold lower after the intravitreal ophthalmic injection of 2mg aflibercept than after the systemic oncological intravenous administration of 4 mg/kg ziv-aflibercept. The Uppsala Monitoring Center (UMC) describes about an increased disproportionality for events of deep vein thrombosis and pulmonary embolism in males compared to females with the use of aflibercept across indications and routes of administration, hypothesizing that male gender may be a potential risk factor for venous thromboembolic events associated with aflibercept. Disproportionality analysis performed by UMC, for the ophthalmologic indications did, however, not reveal a statistically significant finding. Thus there is no support for a signal with use of intravitreal aflibercept. In 23 UMC reports on ophthalmologic aflibercept on DVT and PE, no male predominance was observed (10 male, 13 female). This is inconsistent with their hypothesis of males being a risk group. Furthermore, a cumulative review of worldwide post-marketing IVT aflibercept case reports in the Global Pharmacovigilance Safety Database of the Marketing Authorization Holders (MAHs) of Eylea® (Bayer AG and Regeneron Pharmaceuticals, Inc.) has shown that no predominance of males is observed in post-marketing cases with VTEs.2 UMC cited a paper published by Avery et al3 in support of potential remaining uncertainties with respect to a systemic signal due to plasma VEGF suppression. The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has previously refuted that a clinically relevant safety signal was present based on a comprehensive scientific evaluation of published studies, including the Avery et al paper. Aflibercept is systemically available in two distinct forms: The “free” form of aflibercept is the active drug moiety. Free aflibercept binds endogenous VEGF to form a stable, inert VEGF:aflibercept complex (referred to as bound aflibercept), that is incapable of further VEGF binding and is thus biologically inactive. After IVT administration, aflibercept is slowly absorbed from the eye into the systemic circulation, where it is predominately observed in its bound form, i.e. as the inactive, stable complex with VEGF. The sum of both, free and bound, aflibercept is referred to as total aflibercept. Aflibercept concentrations reported by Avery et al.3 reflect total aflibercept concentrations and therefore largely represent the biologically inactive, bound form of aflibercept. Furthermore, a role for VEGF plasma/serum level modulation as a marker with implications for systemic safety remains highly questionable since the physiological role of the localized acting VEGF in the plasma/serum is unclear and no confirmed link to any untoward affects has been shown. The small amounts of systemic VEGF complexed after IVT administration of 2 mg aflibercept are insufficient to cause a systemic bio-effect as measured by blood pressure changes, which is believed to be a sensitive, robust, and leading indicator of systemic VEGF inhibition. Moreover, assays used to quantify VEGF levels and anti-VEGF levels in plasma/serum reported by these authors were not validated. In contrast it was experimentally shown that the presence of an anti-VEGF compound in the plasma sample interferes with the VEGF quantitation in the assay used resulting in unreliable results.4 This lack of validation is corroborated by the fact that none of the reported adverse events discussed within these publications can be attributed directly to the neutralization of VEGF in plasma or serum. This is fully consistent with the observations in the pivotal Phase III program of aflibercept across all ophthalmologic indications. Thus, none of these publications provide evidence for any clinical systemic safety signal. I.e. no correlation of the reported findings with systemic adverse events was provided and thus the reported disproportionality across indications and routes of administration are considered of no concern for intravitreal use of aflibercept. In conclusion, VTEs are not an identified risk for aflibercept used intravitreally for ophthalmologic indications. No disproportionality or male predominance was detected by UMC in cases with aflibercept in ophthalmologic indications. Cumulative review of VTEs in the MAHs Global Safety Database does not suggest a causal association of VTEs and intravitreal aflibercept and no predominance of males is observed in post-marketing cases with VTEs. The safety observation of suggested higher risk of DVTs and PE in males can be refuted for aflibercept intravitreal (IVT) use in its ophthalmologic indications. References 1. Eylea EU SMPC, dated 08 Sep 2017 2. Data on file, as of 05 March 2018 3. Avery et al. Systemic Pharmacokinetics Following Intravitreal Injectionsof Ranibizumab, Bevacizumab or Aflibercept in Patients with Neovascular AMD. British Journal of Ophthalmology, 2014. 98 (12): p. 1636-1641. 4. ARVO Annual Meeting Abstract 2016. Albert Francis Torri; Camille Georgaros; Ashique Rafique; Giane Sumner. Anti-VEGF Drug Interference in the R&D Systems Quantikine VEGF-A ELISA Kit. http://iovs. arvojournals.org/article.aspx?articleid=2559162 #. WqkRPHgvRoE.email Bayer AG contact: Dr. U. Schmidt-Ott, MD. Email: ursula.schmidt-ott@bayer.com" ;
                                                                                                                                                                                  rdfs:label "Response from Bayer on the intravitreal formulation of aflibercept (Eylea®)" .


###  http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#VEGF/VEGFR_(Vascular_Endothelial_Growth_Factor)_inhibitors
<http://purl.org/OpenPVSignal/Signals/2018_6_aflibercept_deep_vein_thrombosis_pulmonary_embolism.owl#VEGF/VEGFR_(Vascular_Endothelial_Growth_Factor)_inhibitors> rdf:type owl:NamedIndividual ,
                                                                                                                                                                          <http://purl.org/OpenPVSignal/OpenPVSignal.owl#DrugClass> ;
                                                                                                                                                                 <http://purl.org/OpenPVSignal/OpenPVSignal.owl#has_ATC_code> "L01FG" ;
                                                                                                                                                                 rdfs:label "VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors" .


###  Generated by the OWL API (version 4.5.9.2019-02-01T07:24:44Z) https://github.com/owlcs/owlapi
